Biomet rated at sector perform by RBC

RBC Capital Markets analyst William R. Quirk gave Biomet Inc. a rating of sector perform, average risk, in anticipation of 8.8% constant currency revenue growth to $540.9 million. The analyst adjusted its revenue estimate to reflect less negative foreign exchange rates, with an earnings-per-share estimate of $0.46 (in line with Street consensus). Shares of the Warsaw, Ind.-based pharmaceutical company were down $1.99, or 6.00%, at $31.19 on volume of 6,587,047 shares versus the three-month running average of 2,453,130 shares. (Nasdaq: BMET)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.